Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
about
sameAs
A review of complementary and alternative medicine (CAM) by people with multiple sclerosisTreatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosisAdverse effects of immunotherapies for multiple sclerosis: a network meta-analysisSodium channel blockers for neuroprotection in multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisSodium channel blockers for neuroprotection in multiple sclerosisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisInterferon beta for chronic hepatitis BIgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelTreatment for spasmodic dysphonia: limitations of current approaches.Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewSystematic review of clinical practice guidelines related to multiple sclerosisRelating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisProgress of mesenchymal stem cell therapy for neural and retinal diseasesMitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-upReversible central neurogenic hyperventilation in an awake patient with multiple sclerosisEFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesGlatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosisInterferon-β-1b: a review of its use in multiple sclerosisEstablishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSAdherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort StudyTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Quality indicators for multiple sclerosis.Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims dataFingolimod: a review of its use in relapsing-remitting multiple sclerosis.Treatment optimization in multiple sclerosis: report of an international consensus meeting.Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.Childhood multiple sclerosis: a review.Interferon-beta1a for the treatment of multiple sclerosis.Use of natalizumab in multiple sclerosis: current perspectives.Assessing Four Quality Indicators for Multiple Sclerosis Management Through Patient-Reported Data[Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].Mitoxantrone and Analogues Bind and Stabilize i-Motif Forming DNA Sequences.Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.Therapeutic apheresis: history, clinical application, and lingering uncertainties.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.
P2860
Q22252861-E177531D-2C22-4714-8550-2517F590BE50Q24185806-6259CB82-1B1B-4AF1-92F3-5FF97CBD8DEAQ24185820-ED35CADF-F240-4092-AFE5-23DF6EAFB1D4Q24186448-467D528E-099C-4325-B82E-AC097CBE30A0Q24187126-5D52177F-E0AD-417B-B769-223DA4C567A6Q24200461-CC4DD576-03FE-42AC-B28C-1AF156A4AD43Q24202108-9EFA2B98-64CA-4CD7-943E-7070068A2B31Q24235249-5A1D3F9E-16B2-4FF7-8AA4-21728827CB3DQ24235548-8BC145FB-F64B-4D15-B37E-D572C8CC7D25Q24646531-B7E395CB-95CB-4C5F-9CCC-5B1065CED828Q24652227-F4985744-B9BD-4E13-AE43-D7376783D430Q26782408-F72F10AC-AE55-4490-AC1E-0DD666697230Q26824425-77C4FEFF-058A-4F6F-B90B-0251F4791315Q26828463-727F474D-BC82-459F-BCDC-7DB8D0122E68Q27015716-18868563-0B0E-497F-A624-1716F7452A31Q28254413-AFC6E94A-E97F-4C55-B9C9-66D324EEA8DBQ28257391-D93BF333-7983-4BCD-A5AE-5DAF4838124CQ28284851-B13DED6C-3747-420E-8366-54B7153825E0Q28289819-2DE65ED4-A7EF-477E-A5DF-6B42F35DF6B2Q28299838-88451DD0-BDBA-4BA0-85A6-0ACEC5B143A8Q28478190-607DB8CF-919A-4B89-A28A-A64CF78077B8Q28546799-3CE4641D-FBFD-4558-A9EE-4FE5401938FCQ30234672-A0DEFDC9-13CC-40D5-87EB-AE59D7975A9FQ30496036-56AA165A-6C8C-4C4A-94B6-CCB850F00B6DQ30659100-17546770-5779-4299-B0A2-8184DFC55A80Q30834523-2944AF92-B9BA-4297-BE35-E08FA02A6F2AQ30838717-4CAA7E22-5CC3-4F35-A559-59A9F9DAB9A6Q30886689-EF27CF8D-A4CC-493B-93F3-089146D40842Q31039951-30A93D3C-8553-4F01-9070-EFA0F669CBBEQ31047410-AA603E32-AD68-49CE-99E1-9023C4D952D0Q31106233-29BBAE6A-9D3F-47F8-925D-A3D3A257E4BDQ31114633-8F136373-CC2B-478D-AFC8-A8A9FE60F088Q31123075-04A34B18-5C18-47B1-9BD1-1652C9A99675Q31149165-3EA67622-B3F5-4987-A41C-673DB838C45EQ31150627-744556E3-6E0A-47BB-A3B0-0ECCA702D2FFQ31166026-39454969-0429-42D0-AF18-EEC7AD3E891BQ33274608-017A58C8-1A92-4006-8219-B017EA410DFBQ33387254-CF179452-F023-4EDD-9DB0-88647CB8D519Q33500910-C2FF2C70-D7D1-4B99-A13F-DA8D56F52DC6Q33510256-86E12924-92BE-4670-A49C-538C86A8A972
P2860
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
description
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Januar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 22 January 2002)
@en
vedecký článok (publikovaný 2002/01/22)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/01/22)
@nl
наукова стаття, опублікована в січні 2002
@uk
مقالة علمية (نشرت في 22-1-2002)
@ar
name
Disease modifying therapies in ...... r Clinical Practice Guidelines
@ast
Disease modifying therapies in ...... r Clinical Practice Guidelines
@en
Disease modifying therapies in ...... r Clinical Practice Guidelines
@nl
type
label
Disease modifying therapies in ...... r Clinical Practice Guidelines
@ast
Disease modifying therapies in ...... r Clinical Practice Guidelines
@en
Disease modifying therapies in ...... r Clinical Practice Guidelines
@nl
prefLabel
Disease modifying therapies in ...... r Clinical Practice Guidelines
@ast
Disease modifying therapies in ...... r Clinical Practice Guidelines
@en
Disease modifying therapies in ...... r Clinical Practice Guidelines
@nl
P2093
P3181
P356
P1433
P1476
Disease modifying therapies in ...... r Clinical Practice Guidelines
@en
P2093
D H Silberberg
D S Goodin
E M Frohman
F D Lublin
G P Garmany
S van den Noort
W H Likosky
W H Stuart
P304
P3181
P356
10.1212/WNL.58.2.169
P407
P577
2002-01-22T00:00:00Z